Biohaven Pharmaceuticals
Data Breaches, Cyber Attacks and Security Report  ᛫ 
Last updated January 18, 2020

About Biohaven Pharmaceuticals

Company Overview

Rimegepant (BHV-3000; formerly BMS-927711) is an investigational drug candidate for the treatment of migraine. Originally discovered at Bristol-Myers Squibb, it is currently under development by Biohaven Pharmaceuticals.





New Haven, CT, United States.

Data Breaches and Security News

Biohaven Pharmaceuticals Security Rating

Sorry, this security report couldn't be loaded at this time. Please try again later.

UpGuard's Cyber Security Ratings range from 0 to 950. The higher the score, the more likely Biohaven Pharmaceuticals is implementing good security practices.

Passed Checks

Passed{{ passedCheck.passTitle }}

Failed Checks

Warning{{ failedCheck.failTitle }}

View a free security report for Biohaven Pharmaceuticals

Get full security report ›

Related posts

Read more about the latest issues in cybersecurity

More security reports

Compare Biohaven Pharmaceuticals's security performance with other companies